NASDAQ:INCY - Incyte Stock Price, Forecast & News

Incyte trades on the NASDAQ under the ticker symbol "INCY."

Incyte Co. (NASDAQ:INCY) announced its earnings results on Tuesday, October, 29th. The biopharmaceutical company reported $0.82 EPS for the quarter, topping the consensus estimate of $0.55 by $0.27. The biopharmaceutical company earned $551.58 million during the quarter, compared to the consensus estimate of $534.73 million. Incyte had a net margin of 19.21% and a return on equity of 20.07%. Incyte's revenue was up 22.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.41 EPS. View Incyte's Earnings History.

Incyte is scheduled to release their next quarterly earnings announcement on Thursday, February 13th 2020. View Earnings Estimates for Incyte.

Incyte will be holding an earnings conference call on Thursday, February 13th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

22 analysts have issued twelve-month price objectives for Incyte's shares. Their forecasts range from $74.00 to $121.00. On average, they expect Incyte's stock price to reach $92.24 in the next year. This suggests a possible upside of 20.6% from the stock's current price. View Analyst Price Targets for Incyte.

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 10 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Incyte.

News headlines about INCY stock have trended somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Incyte earned a media sentiment score of 0.8 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 3.0 out of 10, meaning that recent press coverage is unlikely to have an impact on the company's share price in the next few days. View News Stories for Incyte.

Incyte saw a decrease in short interest in January. As of January 15th, there was short interest totalling 3,950,000 shares, a decrease of 14.5% from the December 31st total of 4,620,000 shares. Based on an average daily volume of 1,360,000 shares, the short-interest ratio is presently 2.9 days. Currently, 1.9% of the company's shares are sold short. View Incyte's Current Options Chain.

Some companies that are related to Incyte include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL) and Repligen (RGEN).

Based on aggregate information from My MarketBeat watchlists, some companies that other Incyte investors own include Puma Biotechnology (PBYI), Medivation (MDVN), BioMarin Pharmaceutical (BMRN), First Solar (FSLR), United Continental (UAL), Dynavax Technologies (DVAX), Kite Pharma (KITE), Array Biopharma (ARRY), Celgene (CELG) and Micron Technology (MU).

Incyte's stock is owned by many different of institutional and retail investors. Top institutional investors include Manning & Napier Group LLC (0.23%), California Public Employees Retirement System (0.20%), Country Trust Bank (0.18%), Candriam Luxembourg S.C.A. (0.13%), New York State Teachers Retirement System (0.12%) and Virginia Retirement Systems ET AL (0.10%). Company insiders that own Incyte stock include Barry P Flannelly, David W Gryska, Herve Hoppenot, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Reid M Huber, Steven H Stein, Vijay K Iyengar, Wendy L Dixon and Yao Wenqing. View Institutional Ownership Trends for Incyte.

INCY stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Manning & Napier Group LLC, Meag Munich Ergo Kapitalanlagegesellschaft MBH, Nippon Life Global Investors Americas Inc., First Quadrant L P CA, Landsberg Bennett & Dubbaneh LLC, Candriam Luxembourg S.C.A. and First Hawaiian Bank. Company insiders that have sold Incyte company stock in the last year include Barry P Flannelly, Jean Jacques Bienaime, Paul A Friedman, Paul Trower, Paula J Swain, Steven H Stein, Wendy L Dixon and Yao Wenqing. View Insider Buying and Selling for Incyte.

INCY stock was acquired by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., Shikiar Asset Management Inc., Rhenman & Partners Asset Management AB, Patton Fund Management Inc., M&G Investment Management Ltd., California Public Employees Retirement System, Commerzbank Aktiengesellschaft FI and New York State Teachers Retirement System. Company insiders that have bought Incyte stock in the last two years include Herve Hoppenot and Jean Jacques Bienaime. View Insider Buying and Selling for Incyte.

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of INCY stock can currently be purchased for approximately $76.46.

Incyte has a market capitalization of $16.47 billion and generates $1.88 billion in revenue each year. The biopharmaceutical company earns $109.49 million in net income (profit) each year or $0.82 on an earnings per share basis. Incyte employs 1,367 workers across the globe.View Additional Information About Incyte.

The official website for Incyte is http://www.incyte.com/.

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]